Literature DB >> 24023270

Changes in pathological and biochemical findings of systemic tissue sites in familial amyloid polyneuropathy more than 10 years after liver transplantation.

Toshinori Oshima1, Satomi Kawahara2, Mitsuharu Ueda1, Yushi Kawakami2, Rina Tanaka2, Takahiro Okazaki1, Yohei Misumi1, Konen Obayashi2, Taro Yamashita1, Yuki Ohya3, Elisabet Ihse4, Satoru Shinriki2, Masayoshi Tasaki1, Hirofumi Jono2, Katsuhiro Asonuma3, Yukihiro Inomata3, Per Westermark4, Yukio Ando1.   

Abstract

OBJECTIVE: To elucidate the long-term effects of liver transplantation (LT) on familial amyloid polyneuropathy (FAP).
METHODS: We investigated clinicopathological and biochemical characteristics of systemic tissues in four autopsied cases of FAP patients surviving more than 10 years after LT and seven autopsied cases without LT. For analysing the truncated form of transthyretin (TTR) in amyloid, we also employed specimens from additional 18 FAP patients.
RESULTS: Several tissue sites such as the heart, tongue and spinal cord had moderate-to-severe amyloid deposits but other tissues showed no or mild amyloid deposition. Those findings seemed similar to those observed in senile systemic amyloidosis (SSA), a sporadic amyloidosis caused by wild-type (WT) TTR. Also, amyloid deposits in systemic tissue sites except for the spinal cord in patients after LT derived mostly from WT TTR secreted from the normal liver grafts. In addition, in non-transplantation patients, proportions of WT TTR seemed to be relatively high in those tissue sites in which patients after LT had severe amyloid deposition, which suggests that WT TTR tends to form amyloid in those tissue sites. Finally, although the truncation of TTR in amyloid deposits did not depend on undergoing LT, we elucidated the truncation of TTR occurred predominantly in patients from non-endemic areas of Japan, where FAP amyloidogenic TTR V30M patients are late onset and low penetrance, compared with patients from an endemic area of Japan.
CONCLUSIONS: FAP may shift to systemic WT TTR amyloid formation after LT, which seems to be similar to the process in SSA. The truncation of TTR in amyloid deposits may depend on some genetic or environmental factors other than undergoing LT. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  Amyloid; Genetics; Pathology

Mesh:

Substances:

Year:  2013        PMID: 24023270     DOI: 10.1136/jnnp-2013-305973

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  14 in total

Review 1.  Current and Future Treatment Approaches in Transthyretin Familial Amyloid Polyneuropathy.

Authors:  Philippe Kerschen; Violaine Planté-Bordeneuve
Journal:  Curr Treat Options Neurol       Date:  2016-12       Impact factor: 3.598

2.  A cell-based high-throughput screening method to directly examine transthyretin amyloid fibril formation at neutral pH.

Authors:  Mitsuharu Ueda; Masamitsu Okada; Mineyuki Mizuguchi; Barbara Kluve-Beckerman; Kyosuke Kanenawa; Aito Isoguchi; Yohei Misumi; Masayoshi Tasaki; Akihiko Ueda; Akinori Kanai; Ryoko Sasaki; Teruaki Masuda; Yasuteru Inoue; Toshiya Nomura; Satoru Shinriki; Tsuyoshi Shuto; Hirofumi Kai; Taro Yamashita; Hirotaka Matsui; Merrill D Benson; Yukio Ando
Journal:  J Biol Chem       Date:  2019-06-05       Impact factor: 5.157

Review 3.  FAP neuropathy and emerging treatments.

Authors:  David Adams; Marie Théaudin; Cecile Cauquil; Vincent Algalarrondo; Michel Slama
Journal:  Curr Neurol Neurosci Rep       Date:  2014-03       Impact factor: 5.081

Review 4.  Newer Therapies for Amyloid Cardiomyopathy.

Authors:  Rajshekhar Chakraborty; Eli Muchtar; Morie A Gertz
Journal:  Curr Heart Fail Rep       Date:  2016-10

Review 5.  Iatrogenic amyloid polyneuropathy after domino liver transplantation.

Authors:  Diana Mnatsakanova; Saša A Živković
Journal:  World J Hepatol       Date:  2017-01-28

6.  Development of transgenic Caenorhabditis elegans expressing human transthyretin as a model for drug screening.

Authors:  Yukimoto Tsuda; Kunitoshi Yamanaka; Risa Toyoshima; Mitsuharu Ueda; Teruaki Masuda; Yohei Misumi; Teru Ogura; Yukio Ando
Journal:  Sci Rep       Date:  2018-12-14       Impact factor: 4.379

Review 7.  Ocular Manifestations and Therapeutic Options in Patients with Familial Amyloid Polyneuropathy: A Systematic Review.

Authors:  A C Martins; A M Rosa; E Costa; C Tavares; M J Quadrado; J N Murta
Journal:  Biomed Res Int       Date:  2015-10-19       Impact factor: 3.411

Review 8.  Recent advances in transthyretin amyloidosis therapy.

Authors:  Mitsuharu Ueda; Yukio Ando
Journal:  Transl Neurodegener       Date:  2014-09-13       Impact factor: 8.014

9.  Involvement of Macrophages in the Pathogenesis of Familial Amyloid Polyneuropathy and Efficacy of Human iPS Cell-Derived Macrophages in Its Treatment.

Authors:  Genki Suenaga; Tokunori Ikeda; Yoshihiro Komohara; Koutaro Takamatsu; Tatsuyuki Kakuma; Masayoshi Tasaki; Yohei Misumi; Mitsuharu Ueda; Takaaki Ito; Satoru Senju; Yukio Ando
Journal:  PLoS One       Date:  2016-10-03       Impact factor: 3.240

Review 10.  Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm.

Authors:  Yoshiki Sekijima; Mitsuharu Ueda; Haruki Koike; Sonoko Misawa; Tomonori Ishii; Yukio Ando
Journal:  Orphanet J Rare Dis       Date:  2018-01-17       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.